ArticleRevista medica del Instituto Mexicano del Seguro Social2022
[Survival in pediatric patients with pneumonia in coronavirus disease 2019].
Article in Revista medica del Instituto Mexicano del Seguro Social, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.
- Risk Factors for Pediatric Critical COVID-19: A Systematic Review and Meta-Analysis.Journal of the Pediatric Infectious Diseases Society · 2024Pooled it
- Risk Factors for Pediatric Critical COVID-19: A Systematic Review and Meta-Analysis.medRxiv : the preprint server for health sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: A segment of children and adolescents with coronavirus disease 2019 (COVID-19) develops pneumonia and published evidence regarding its prognostic factors in this specific population is scarce. Objective: To characterize the survival of children and adolescents hospitalized for pneumonia related to COVID-19, as well as to evaluate prognostic factors for disease's outcomes. Material and methods: A cohort study was performed in Mexico and data from hospitalized children and adolescents with COVID-19 related pneumonia were analyzed. We used the Kaplan-Meier method to estimate survival functions and 95% confidence intervals (95% CI), as well as Cox proportional-hazards regressions to evaluate the association of the evaluated exposures with the outcomes of disease. Results: A total of 1423 patients were recruited for a follow-up of 15,188 person-days and the overall rate of in-hospital mortality (n = 208) was 13.7 per 1000 person-days. The survival function was 96.5% (95% CI 95.2-97.4%) and 69.3% (95% CI 63.9-74.0) of hospital stay, respectively. In multiple analysis, the history of immunosuppression was associated with an increased risk of a fatal outcome (hazard ratio [HR] = 2.70, IC 95% 1.38-5.30). Conclusions: We characterized the survival of a large cohort of children and adolescents with COVID-19 related pneumonia. The presented findings suggest that minors with a history of immunosuppression and pneumonia have an increased risk of fatal outcome.
Indexed as
Identifiers
36048629PMC10395966W4294125889What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.